RetiSpec is a Toronto-based medical AI company that aims to enable widespread early and accurate detection of neurodegenerative disease markers through a simple eye exam. RetiSpec's AI solutions applied to non-invasive retinal images, provide real-time results at the point of care. RetiSpec's first clinically validated AI is intended to predict amyloid burden to aid in the evaluation of individuals for Alzheimer's disease. RetiSpec's AI solutions are currently available for Research Use Only.